- Exyte offers the new ExyCellR modular technology for fast-track construction of biologicals production facilities compliant with the current good manufacturing practice (cGMP).
- Univercells Technologies delivers the integrated NevoLine™ biomanufacturing platform, including scale-X™ bioreactors, for low footprint and economic large-scale production of viral products.
- The combined offer enables users to rapidly deploy prefabricated GMP vaccine manufacturing facilities in response to new disease outbreaks.
Pharmaceutical manufacturers find themselves at a critical juncture. In the past 30 years, pharma has seen some significant shifts. Consider the expanding range of drug therapies, once confined almost exclusively to small molecule drugs. Biologics now comprise a substantial share of the market, and novel treatments such as cell and gene therapies are rapidly gaining traction. Another major trend is the rise of outsourced manufacturing, primarily for small molecule drugs.
This Congress will explore the novel technologies and manufacturing strategies accelerating the efficient production of next-generation biologics.
With 30+ presentations over two days, this meeting focuses on key challenges within the field, evaluating innovative solutions such as continuous bioprocessing, SUTs, data integrity, PAT and the implementation of industry 4.0, all of which aim to increase the efficiency and yield of therapeutic production whilst maintaining high-quality standards. Once again, this meeting will also feature a track dedicated to the manufacturing of cell and gene therapies, exploring both the regulatory and manufacturing challenges of these complex products.
The digital transformation of biopharmaceutical manufacturing is continuing at a rapid pace as companies attempt to mine the sources of data available. Innovations include predictive analytics, big data analytics, and creating the digital plant. Digital transformation offers a mechanism to revise its business model, to improve production processes, to design new drugs faster by using artificial intelligence to screen compounds and to increase responsiveness to customers. Furthermore, the volume of data processed by pharmaceutical firms shows no sign of slowing down. This means pharmaceutical companies must act quickly in terms of building core internal digital capabilities and moving beyond their traditional IT functions to all areas of the business.